Show simple item record

dc.contributor.authorChamberlain, F
dc.contributor.authorBenson, C
dc.contributor.authorThway, K
dc.contributor.authorHuang, P
dc.contributor.authorJones, RL
dc.contributor.authorGennatas, S
dc.date.accessioned2021-09-21T13:41:29Z
dc.date.available2021-09-21T13:41:29Z
dc.date.issued2021-04-21
dc.identifier.citationFuture oncology (London, England), 2021
dc.identifier.issn1479-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4822
dc.identifier.eissn1744-8301
dc.identifier.eissn1744-8301en_US
dc.identifier.doi10.2217/fon-2020-1092
dc.identifier.doi10.2217/fon-2020-1092en_US
dc.description.abstractLiposarcomas are rare tumors arising from adipocytic tissue and accounting for approximately 15-20% of all soft tissue sarcomas. Liposarcoma can be further classified into histopathological subtypes with variable chemosensitivity according to subtype. Decisions regarding management should be made on an individual basis, but surgery for localized disease and systemic chemotherapy remain the mainstay of treatment. Currently, only doxorubicin and trabectedin have robust Phase III data to support their use in the management of advanced liposarcoma. However, in the subgroup analysis of a Phase III trial comparing eribulin with dacarbazine, there was a greater than 7-month improvement in median overall survival in those treated with eribulin. There are also promising results from emerging studies in novel and targeted agents for the treatment of liposarcoma.
dc.formatPrint-Electronic
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0
dc.titlePharmacotherapy for liposarcoma: current and emerging synthetic treatments.
dc.typeJournal Article
dcterms.dateAccepted2021-03-18
rioxxterms.versionVoR
rioxxterms.versionofrecord10.2217/fon-2020-1092
rioxxterms.licenseref.startdate2021-04-21
rioxxterms.licenseref.startdate2021-04-21en_US
dc.relation.isPartOfFuture oncology (London, England)
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.embargo.termsNot known
icr.researchteamSarcoma Clinical Trials (R Jones)
icr.researchteamMolecular and Systems Oncology
icr.researchteamSarcoma Clinical Trials (R Jones)en_US
icr.researchteamMolecular and Systems Oncologyen_US
dc.contributor.icrauthorHuang, Paulen
dc.contributor.icrauthorJones, Robinen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-sa/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-sa/4.0